Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Colorectal Neoplasms 6Stomach Neoplasms 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Neoplasms 4Nasopharyngeal Carcinoma 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Advanced Solid Tumors 2von Hippel-Lindau Disease 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Adenocarcinoma 1Solid Tumors 1Solid Tumor, Adult 1Solid Tumor 1

Interventions

Imatinib Mesylate 12Sunitinib 10ripretinib 5regorafenib 4Blood Specimen Collection 3envafolimab 2Specimen Handling 2Paclitaxel 2Magnetic Resonance Spectroscopy 2IDRX-42 2Biopsy 2trastuzumab deruxtecan 1spartalizumab 1ribociclib 1pemigatinib 1palbociclib 1olverembatinib 1nilotinib 1guadecitabine 1binimetinib 1avelumab 1avapritinib 1atezolizumab 1apatinib 1Temozolomide 1TAS-116 1Surgical Instruments 1Sorafenib 1Rogaratinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × spartalizumab × 1 year × Clear all
NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Novartis

Phase 1 Terminated
122 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡